Nancy Agrawal

1.5k citations

39 papers · 1.1k indexed · h-index 20

Impact in

Pharmacology top 2%
- Inflammatory mediators and NSAID effects
- Pharmacogenetics and Drug Metabolism
Biochemistry top 10%
- Eicosanoids and Hypertension Pharmacology

Papers in

Pharmacology 15
- Inflammatory mediators and NSAID effects 19
- Pharmacogenetics and Drug Metabolism 15
Biochemistry 4
- Eicosanoids and Hypertension Pharmacology 4

Co-authors: Keith Gottesdiener Eric Woolf John A. Wagner Arturo G. Porras Catherine Z. Matthews Jules I. Schwartz Eric H. Rubin Evan Friedman
Journals: The Journal of Clinical Pharmacology (15 papers)Cancer Chemotherapy and Pharmacology (4 papers)Journal of Clinical Oncology (2 papers)British Journal of Clinical Pharmacology (2 papers)Drug Metabolism and Disposition (2 papers)
Partner nations: United States United Kingdom Belgium

In The Last Decade

Nancy Agrawal

39 papers receiving 1.0k citations

Peers

Countries citing papers authored by Nancy Agrawal

Since Specialization

Citations

This map shows the geographic impact of Nancy Agrawal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nancy Agrawal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nancy Agrawal more than expected).

Fields of papers citing papers by Nancy Agrawal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nancy Agrawal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nancy Agrawal. The network helps show where Nancy Agrawal may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Nancy Agrawal, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Nancy Agrawal Line = papers co-authored together Nancy Agrawal links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Comparison of Deconvolution-Based and Absorption Modeling IVIVC for Extended Release Formulations of a BCS III Drug Development Candidate The AAPS Journal ·Filippos Kesisoglou, Binfeng Xia, Nancy Agrawal	2015	36
2	Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor Cancer Chemotherapy and Pharmacology ·Marian Iwamoto, Evan Friedman, Punam Sandhu, Nancy Agrawal, Eric H. Rubin, John A. Wagner	2013	58
3	The minimal impact of food on the pharmacokinetics of ridaforolimus Cancer Chemotherapy and Pharmacology ·Mark Stroh, Xiaodong Li, Gabrielle de Carli, Deborah Panebianco, Amy O. Johnson‐Levonas, 勲佐々, Keith Orford, Nancy Agrawal, Michele Trucksis, John A. Wagner, Gail Murphy, Marian Iwamoto	2012	4
4	The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus Cancer Chemotherapy and Pharmacology ·Mark Stroh, John Palcza, Jacqueline B. McCrea, Gabrielle de Carli, Sheila Breidinger, Deborah Panebianco, Amy O. Johnson‐Levonas, Walter K. Kraft, Keith Orford, Gail Murphy, Nancy Agrawal, Michele Trucksis, John A. Wagner, Marian Iwamoto	2012	5
5	A phase I trial of MK-0731, a Kinesin Spindle Protein (KSP) inhibitor, in patients with solid tumors Investigational New Drugs ·Kyle D. Holen, Robert S. DiPaola, Glenn Liu, Antoinette R. Tan, George Wilding, Karl Hsu, Nancy Agrawal, Cong Chen, 博史宮永, Elizabeth Rosenberg, Mark N. Stein	2011	50
6	Examination of the Effect of Increasing Doses of Etoricoxib on Oral Methotrexate Pharmacokinetics in Patients With Rheumatoid Arthritis The Journal of Clinical Pharmacology ·Jules I. Schwartz, Nancy Agrawal, Peggy H. Wong, Jutta Miller, Kenneth Bachmann, Thomas Marbury, David Hoelscher, Paul F. Cavanaugh, Keith Gottesdiener	2009	18
7	Tolerability, pharmacokinetics and night‐time effects on postural sway and critical flicker fusion of gaboxadol and zolpidem in elderly subjects British Journal of Clinical Pharmacology ·Julia Boyle, Philippe Danjou, Robert Alexander, Nicole Calder, Cynthia Gargano, Nancy Agrawal, I. Fu, Jacqueline B. McCrea, M. Gail Murphy	2008	25
8	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Taranabant, a Novel Selective Cannabinoid‐1 Receptor Inverse Agonist, for the Treatment of Obesity: Results From a Double‐Blind, Placebo‐Controlled, Single Oral Dose Study in Healthy Volunteers The Journal of Clinical Pharmacology ·Carol Addy, N. A. Scherbov, Nancy Agrawal, Julie A. Stone, Anup Majumdar, L. Zhong, Hankun Li, Jinyu Yuan, Andrea Maes, Paul Rothenberg, Josée Côté, Kim Rosko, Ángel Martínez‐Vásquez, Steve Warrington, Malcolm Boyce, Keith Gottesdiener, Aubrey Stoch, John A. Wagner	2008	39
9	Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib British Journal of Clinical Pharmacology ·Jules I. Schwartz, Nancy Agrawal, Martin Wehling, Bret J. Musser, Staff Sergeant Amanda McCarty, N. Michiels, Marina De Smet, John A. Wagner	2008	12
10	Lack of Effect of Antacids on Single‐Dose Pharmacokinetics of Etoricoxib The Journal of Clinical Pharmacology ·Jules I. Schwartz, Nancy Agrawal, Uma Kher, L. Blakee, Paul F. Cavanaugh, Michel Guillaume, David L. Ebel, Hao-Jen You, John A. Wagner	2007	9
11	The Effect of Etoricoxib on the Pharmacodynamics and Pharmacokinetics of Warfarin The Journal of Clinical Pharmacology ·Jules I. Schwartz, Nancy Agrawal, Alan Hartford, Josée Côté, Thomas L. Hunt, René Verbesselt, Corinna Wulf, Keith Gottesdiener	2007	12
12	METABOLISM AND DISPOSITION OF A POTENT AND SELECTIVE GABA-Aα2/3 RECEPTOR AGONIST IN HEALTHY MALE VOLUNTEERS Drug Metabolism and Disposition ·P.C. Conor, S. Vickers, Donghui Cui, Raju Subramanian, Byron H. Arison, Nancy Agrawal, Brynn Knowlton, S Montri, M. Gail Murphy, Kenneth C. Lasseter, Richard C. Simpson, José M. Vega, A. David Rodrigues	2006	9
13	Etoricoxib in acute pain associated with dental surgery: A randomized, double-blind, placebo- and active comparator-controlled dose-ranging study Clinical Therapeutics ·Kerstin Malmström, Aditi Sapre, Mattityahu Zolti, Nancy Agrawal, Ralph S. Mazenko, James R. Fricke	2004	69
14	Pharmacokinetics of Etoricoxib in Patients with Renal Impairment The Journal of Clinical Pharmacology ·Nancy Agrawal, Catherine Z. Matthews, Ralph S. Mazenko, W. F. Kline, Eric Woolf, Arturo G. Porras, Leslie A. Geer, Peggy H. Wong, Yeung-Bae Chae, Josée Côté, Thomas Marbury, Jack W. Moncrief, Harry Alcorn, Suzanne K. Swan, Marshall Sack, Richard A. Robson, Kevin J. Petty, Jules I. Schwartz, Keith Gottesdiener	2003	32
15	Pharmacokinetic Evaluation of Rofecoxib Clinical Drug Investigation ·Jules I. Schwartz, Patrick Larson, Arturo G. Porras, Greg Marchetti, Nancy Agrawal, Kenneth C. Lasseter, Ralph S. Mazenko, E Shinko, Barry J. Gertz	2003	2
16	Pharmacokinetics of Etoricoxib in Patients with Hepatic Impairment The Journal of Clinical Pharmacology ·Nancy Agrawal, Mark J. Rose, Catherine Z. Matthews, Eric Woolf, Arturo G. Porras, Leslie A. Geer, Patrick Larson, Josée Côté, Stacy C. Dilzer, Kenneth C. Lasseter, Imtiaz Alam, Kevin J. Petty, Keith Gottesdiener	2003	19
17	An Evaluation of the Dose‐Dependent Inhibition of CYP1A2 by Rofecoxib Using Theophylline as a CYP1A2 Probe The Journal of Clinical Pharmacology ·Kenneth Bachmann, Donald B. White, Luis Jáuregui, Jules I. Schwartz, Nancy Agrawal, Ralph S. Mazenko, Patrick Larson, Arturo G. Porras	2003	21
18	Absorption, Metabolism, and Excretion of Etoricoxib, a Potent and Selective Cyclooxygenase-2 Inhibitor, in Healthy Male Volunteers Drug Metabolism and Disposition ·A. David Rodrigues, Rita A. Halpin, Leslie A. Geer, Donghui Cui, Eric Woolf, Catherine Z. Matthews, Keith Gottesdiener, Patrick Larson, Kenneth C. Lasseter, Nancy Agrawal	2003	64
19	Simultaneous determination of unlabeled and carbon‐13‐labeled etoricoxib, a new cyclooxygenase‐2 inhibitor, in human plasma using HPLC–MS/MS Journal of Pharmaceutical Sciences ·Mark J. Rose, Nancy Agrawal, Eric Woolf, B.K. Matuszewski	2002	23
20	Dose Proportionality of Oral Etoricoxib, a Highly Selective Cyclooxygenase‐2 Inhibitor, in Healthy Volunteers The Journal of Clinical Pharmacology ·Nancy Agrawal, Arturo G. Porras, Catherine Z. Matthews, Eric Woolf, Jutta Miller, Saurabh Mukhopadhyay, Zuoxun Fan, Keith Gottesdiener	2001	52

About Nancy Agrawal

Nancy Agrawal is a scholar working on Pharmacology, Pharmacology, Biochemistry, Process Chemistry and Technology and Oncology, having authored 39 papers that have together received 1.1k indexed citations. Recurring topics across this work include Inflammatory mediators and NSAID effects (19 papers), Pharmacogenetics and Drug Metabolism (15 papers), Eicosanoids and Hypertension Pharmacology (4 papers), Microtubule and mitosis dynamics (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers), Cancer Treatment and Pharmacology (3 papers), Estrogen and related hormone effects (3 papers) and Biochemical and Molecular Research (2 papers). The work is most often cited by research in Pharmacology (470 citations), Pharmacology (175 citations), Biochemistry (82 citations), Pharmaceutical Science (67 citations) and Anesthesiology and Pain Medicine (47 citations). Nancy Agrawal has collaborated with scholars based in United States, United Kingdom and Belgium. Frequent co-authors include Keith Gottesdiener, Eric Woolf, John A. Wagner, Arturo G. Porras, Catherine Z. Matthews, Jules I. Schwartz, Eric H. Rubin, Evan Friedman, Marian Iwamoto and Ralph S. Mazenko. Their work appears in journals such as The Journal of Clinical Pharmacology, Cancer Chemotherapy and Pharmacology, Journal of Clinical Oncology, British Journal of Clinical Pharmacology and Drug Metabolism and Disposition.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact